These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 25214764)

  • 1. Combining structure-based pharmacophore modeling, virtual screening, and in silico ADMET analysis to discover novel tetrahydro-quinoline based pyruvate kinase isozyme M2 activators with antitumor activity.
    Chen C; Wang T; Wu F; Huang W; He G; Ouyang L; Xiang M; Peng C; Jiang Q
    Drug Des Devel Ther; 2014; 8():1195-210. PubMed ID: 25214764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and structure-activity relationship of novel 4-hydroxy-thiazolidine-2-thione derivatives as tumor cell specific pyruvate kinase M2 activators.
    Li R; Ning X; Zhou S; Lin Z; Wu X; Chen H; Bai X; Wang X; Ge Z; Li R; Yin Y
    Eur J Med Chem; 2018 Jan; 143():48-65. PubMed ID: 29172082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of boronic acid-based potent activators of tumor pyruvate kinase M2 and development of gastroretentive nanoformulation for oral dosing.
    Patle R; Shinde S; Patel S; Maheshwari R; Jariyal H; Srivastava A; Chauhan N; Globisch C; Jain A; Tekade RK; Shard A
    Bioorg Med Chem Lett; 2021 Jun; 42():128062. PubMed ID: 33901643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of novel 7-azaindole derivatives containing pyridin-3-ylmethyl dithiocarbamate moiety as potent PKM2 activators and PKM2 nucleus translocation inhibitors.
    Liu B; Yuan X; Xu B; Zhang H; Li R; Wang X; Ge Z; Li R
    Eur J Med Chem; 2019 May; 170():1-15. PubMed ID: 30878825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of novel sulfonamide derivatives containing pyridin-3-ylmethyl 4-(benzoyl)piperazine-1-carbodithioate moiety as potent PKM2 activators.
    Li R; Ning X; He J; Lin Z; Su Y; Li R; Yin Y
    Bioorg Chem; 2021 Mar; 108():104653. PubMed ID: 33517002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and structure-guided fragment-linking of 4-(2,3-dichlorobenzoyl)-1-methyl-pyrrole-2-carboxamide as a pyruvate kinase M2 activator.
    Matsui Y; Yasumatsu I; Asahi T; Kitamura T; Kanai K; Ubukata O; Hayasaka H; Takaishi S; Hanzawa H; Katakura S
    Bioorg Med Chem; 2017 Jul; 25(13):3540-3546. PubMed ID: 28511909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and development of Tetrahydro-Quinoline derivatives as dual mTOR-C1/C2 inhibitors for the treatment of lung cancer.
    Chaube UJ; Rawal R; Jha AB; Variya B; Bhatt HG
    Bioorg Chem; 2021 Jan; 106():104501. PubMed ID: 33280832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based virtual screening and biological evaluation of novel non-bisphosphonate farnesyl pyrophosphate synthase inhibitors.
    Liu Q; Miao Y; Wang X; Lv G; Peng Y; Li K; Li M; Qiu L; Lin J
    Eur J Med Chem; 2020 Jan; 186():111905. PubMed ID: 31785819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of 3-(trifluoromethyl)-1H-pyrazole-5-carboxamide activators of the M2 isoform of pyruvate kinase (PKM2).
    Xu Y; Liu XH; Saunders M; Pearce S; Foulks JM; Parnell KM; Clifford A; Nix RN; Bullough J; Hendrickson TF; Wright K; McCullar MV; Kanner SB; Ho KK
    Bioorg Med Chem Lett; 2014 Jan; 24(2):515-9. PubMed ID: 24374270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyruvate kinase isozyme M2 and glutaminase might be promising molecular targets for the treatment of gastric cancer.
    Kitayama K; Yashiro M; Morisaki T; Miki Y; Okuno T; Kinoshita H; Fukuoka T; Kasashima H; Masuda G; Hasegawa T; Sakurai K; Kubo N; Hirakawa K; Ohira M
    Cancer Sci; 2017 Dec; 108(12):2462-2469. PubMed ID: 29032577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
    Zhai X; Bao G; Wang L; Cheng M; Zhao M; Zhao S; Zhou H; Gong P
    Bioorg Med Chem; 2016 Mar; 24(6):1331-45. PubMed ID: 26897090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activators of PKM2 in cancer metabolism.
    Warner SL; Carpenter KJ; Bearss DJ
    Future Med Chem; 2014 Jun; 6(10):1167-78. PubMed ID: 25078136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of carbazole derivatives as novel allosteric MEK inhibitors by pharmacophore modeling and virtual screening.
    Xi D; Niu Y; Li H; Noha SM; Temml V; Schuster D; Wang C; Xu F; Xu P
    Eur J Med Chem; 2019 Sep; 178():802-817. PubMed ID: 31252285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and In Vitro Evaluation of Tetrahydroquinoline Derivatives as Antiproliferative Compounds of Breast Cancer via Targeting the GPER.
    Zacarías-Lara OJ; Méndez-Luna D; Martínez-Ruíz G; García-Sanchéz JR; Fragoso-Vázquez MJ; Bello M; Becerra-Martínez E; García-Vázquez JB; Correa-Basurto J
    Anticancer Agents Med Chem; 2019; 19(6):760-771. PubMed ID: 30451119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of tetrahydroquinoline-based reversible LSD1 inhibitors.
    Wang X; Zhang C; Zhang X; Yan J; Wang J; Jiang Q; Zhao L; Zhao D; Cheng M
    Eur J Med Chem; 2020 May; 194():112243. PubMed ID: 32229389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel and selective CDK4/6 inhibitors by pharmacophore and structure-based virtual screening.
    Yuan K; Min W; Wang X; Li J; Kuang W; Zhang F; Xie S; Yang P
    Future Med Chem; 2020 Jun; 12(12):1121-1136. PubMed ID: 32400188
    [No Abstract]   [Full Text] [Related]  

  • 17. Pyruvate kinase activators as a therapy target: a patent review 2011-2017.
    Adem S; Comakli V; Uzun N
    Expert Opin Ther Pat; 2018 Jan; 28(1):61-68. PubMed ID: 28994333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyruvate kinase type M2 contributes to the development of pancreatic ductal adenocarcinoma by regulating the production of metabolites and reactive oxygen species.
    Yokoyama M; Tanuma N; Shibuya R; Shiroki T; Abue M; Yamamoto K; Miura K; Yamaguchi K; Sato I; Tamai K; Satoh K
    Int J Oncol; 2018 Mar; 52(3):881-891. PubMed ID: 29393401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-Guided Approach to Discover Tuberosin as a Potent Activator of Pyruvate Kinase M2, Targeting Cancer Therapy.
    Adnan M; Shamsi A; Elasbali AM; Siddiqui AJ; Patel M; Alshammari N; Alharethi SH; Alhassan HH; Bardakci F; Hassan MI
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyruvate kinase modulators as a therapy target: an updated patent review 2018-2023.
    Adem S; Rasul A; Riaz S; Sadiqa A; Ahmad M; Shahid Nazir M; Hassan M
    Expert Opin Ther Pat; 2024 Oct; 34(10):953-962. PubMed ID: 39279560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.